{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:05:44Z","timestamp":1792872344807,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370604"],"award-info":[{"award-number":["82370604"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Major Science and Technology innovation Project of Fujian Province","award":["2023Y9269"],"award-info":[{"award-number":["2023Y9269"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2023J01239"],"award-info":[{"award-number":["2023J01239"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04289-w","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:06:43Z","timestamp":1761314803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of TDF, TAF, TMF, and TDF-to-TAF switch in chronic hepatitis B: a network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Shuqi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huatang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"4289_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X231168292","volume":"11","author":"WC Sithole","year":"2023","unstructured":"Sithole WC, Pillay S, Mbanjwa B, Magula N. A convoluted path to the diagnosis of hepatocellular carcinoma in a resource-limited setting. SAGE Open Med Case Rep. 2023;11:2050313x231168292.","journal-title":"SAGE Open Med Case Rep"},{"key":"4289_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061358","author":"T Kanda","year":"2019","unstructured":"Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20061358.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4289_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12876-023-03027-4","volume":"23","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhao Z, Ma X, Liu S, Xin Y. Renal and bone side effects of long-term use of entecavir, Tenofovir disoproxil fumarate, and Tenofovir alafenamide fumarate in patients with hepatitis B: a network meta-analysis. BMC Gastroenterol. 2023;23(1):384.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"4289_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3947\/ic.2020.52.3.381","volume":"52","author":"JW Seo","year":"2020","unstructured":"Seo JW, Kim K, Jun KI, Kang CK, Moon SM, Song KH, et al. Recovery of tenofovir-induced nephrotoxicity following switch from tenofovir disoproxil fumarate to tenofovir alafenamide in human immunodeficiency virus-positive patients. Infect Chemother. 2020;52(3):381\u20138.","journal-title":"Infect Chemother"},{"issue":"2","key":"4289_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.5582\/bst.2024.01062","volume":"18","author":"F Zhao","year":"2024","unstructured":"Zhao F, Lu H. Renal safety of Tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review. Biosci Trends. 2024;18(2):141\u201352.","journal-title":"Biosci Trends"},{"issue":"S1","key":"4289_CR6","first-page":"10","volume":"32","author":"Z Hua","year":"2024","unstructured":"Hua Z. [Observation on the efficacy of Zhenqi Fuzheng capsule combined with Tenofovir Amibufenamide in the treatment of chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi. 2024;32(S1):10\u20133.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"1","key":"4289_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10238-025-01584-4","volume":"25","author":"Y Hu","year":"2025","unstructured":"Hu Y, Zhang Y, Jiang W. Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments. Clin Exp Med. 2025;25(1):57.","journal-title":"Clin Exp Med"},{"issue":"7","key":"4289_CR8","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE. 2014;9(7):e99682.","journal-title":"PLoS ONE"},{"issue":"4","key":"4289_CR9","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082.","journal-title":"PLoS Med"},{"key":"4289_CR10","doi-asserted-by":"publisher","first-page":"1165990","DOI":"10.3389\/fphar.2023.1165990","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Zhou J, Li Y, Wang F, Zhang D, Wang M, Tao Y, Chen E. Effectiveness and safety of Tenofovir Amibufenamide and its comparison with Tenofovir Alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study. Front Pharmacol. 2023;14:1165990.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4289_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/13596535241284226","volume":"29","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Xu J, Liu D, Wang L, Ren S, Zheng S, et al. Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: a single-centre retrospective study. Antivir Ther. 2024;29(5):13596535241284226.","journal-title":"Antivir Ther"},{"issue":"44","key":"4289_CR12","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.3748\/wjg.v29.i44.5907","volume":"29","author":"WT Peng","year":"2023","unstructured":"Peng WT, Jiang C, Yang FL, Zhou NQ, Chen KY, Liu JQ, et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: a real-world study. World J Gastroenterol. 2023;29(44):5907\u201318.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"4289_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.14029","volume":"32","author":"X Rong","year":"2025","unstructured":"Rong X, Yang G, Xu Y, Chen H, Wang X, Fu J, et al. Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for first-time HBV-related decompensated cirrhosis. J Viral Hepat. 2025;32(4):e14029.","journal-title":"J Viral Hepat"},{"issue":"3","key":"4289_CR14","first-page":"207","volume":"13","author":"Y Li","year":"2025","unstructured":"Li Y, Lin Y, Gou G, Cui D, Gao X, Xu G, et al. Effectiveness and safety of Tenofovir Amibufenamide in the treatment of chronic hepatitis B: a real-world, multicenter study. J Clin Transl Hepatol. 2025;13(3):207\u201315.","journal-title":"J Clin Transl Hepatol"},{"key":"4289_CR15","first-page":"S312","volume":"80","author":"QL Zeng","year":"2024","unstructured":"Zeng QL, Chen RY, Lv XY, EFFECTIVENESS AND SAFETY OF 48-WEEK TENOFOVIR AMIBUFENAMIDE VS TENOFOVIR ALAFENAMIDE FUMARATE FOR PATIENTS WITH CHRONIC HEPATITIS B. A RETROSPECTIVE REAL-WORLD STUDY. Hepatology. 2024;80:S312.","journal-title":"Hepatology"},{"issue":"9","key":"4289_CR16","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.16611","volume":"54","author":"Z Liu","year":"2021","unstructured":"Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021;54(9):1134\u201349.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"4289_CR17","first-page":"649","volume":"11","author":"Z Liu","year":"2023","unstructured":"Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, et al. 96-Week treatment of Tenofovir Amibufenamide and Tenofovir disoproxil fumarate in chronic hepatitis B patients. J Clin Transl Hepatol. 2023;11(3):649\u201360.","journal-title":"J Clin Transl Hepatol"},{"issue":"11","key":"4289_CR18","first-page":"976","volume":"32","author":"RY Chen","year":"2024","unstructured":"Chen RY, Lyu XY, Huang S, Li WZ, Zhai ZZ, Wang YH, et al. Comparative therapeutic efficacy of Tenofovir amibufenamide versus Tenofovir alafenamide in the treatment of patients with chronic hepatitis B: a real-world single- center study. Zhonghua Gan Zang Bing Za Zhi. 2024;32(11):976\u201383.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"3","key":"4289_CR19","first-page":"252","volume":"31","author":"QJ Sheng","year":"2023","unstructured":"Sheng QJ, Han C, Li YW, Zhang C, Dou XG, Ding Y. Clinical efficacy analysis of TMF for the treatment of hyperviremia HBeAg-positive chronic hepatitis B patients with incomplete response to first-line oral antiviral nucleos(t)ide analogues. Zhonghua Gan Zang Bing Za Zhi. 2023;31(3):252\u20137.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"12","key":"4289_CR20","first-page":"1123","volume":"32","author":"JS Zhang","year":"2024","unstructured":"Zhang JS, Zhao KZ, Li W, Li Y, Hu XX. [Comparison of the effects of Tenofovir Amibufenamide and Tenofovir Alafenamide on lipid metabolism in the body]. Zhonghua Gan Zang Bing Za Zhi. 2024;32(12):1123\u201333.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"5","key":"4289_CR21","doi-asserted-by":"publisher","first-page":"e0251552","DOI":"10.1371\/journal.pone.0251552","volume":"16","author":"CQ Pan","year":"2021","unstructured":"Pan CQ, Chang TT, Bae SH, Brunetto M, Seto WK, Coffin CS, et al. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. PLoS ONE. 2021;16(5):e0251552.","journal-title":"PLoS ONE"},{"issue":"3","key":"4289_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"4289_CR23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.14309\/ctg.0000000000000749","volume":"15","author":"T Huynh Phuong Nguyen","year":"2024","unstructured":"Huynh Phuong Nguyen T, Thi Huong Bui Q, Duy Vo T. Clinical efficacy and safety of long-term treatment of Tenofovir Alafenamide vs Tenofovir disoproxil fumarate for chronic hepatitis B in Vietnam. Clin Transl Gastroenterol. 2024;15(10):e1.","journal-title":"Clin Transl Gastroenterol"},{"issue":"7","key":"4289_CR24","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/liv.15261","volume":"42","author":"J Lim","year":"2022","unstructured":"Lim J, Choi WM, Shim JH, Lee D, Kim KM, Lim YS, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-na\u00efve chronic hepatitis B. Liver Int. 2022;42(7):1517\u201327.","journal-title":"Liver Int"},{"issue":"3","key":"4289_CR25","first-page":"324","volume":"9","author":"J Hou","year":"2021","unstructured":"Hou J, Ning Q, Duan Z, Chen Y, Xie Q, Wang FS, Zhang L, Wu S, Tang H, Li J, et al. 3-year treatment of Tenofovir Alafenamide vs. Tenofovir disoproxil fumarate for chronic HBV infection in China. J Clin Transl Hepatol. 2021;9(3):324\u201334.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"4289_CR26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12879-021-06237-x","volume":"21","author":"J Li","year":"2021","unstructured":"Li J, Hu C, Chen Y, Zhang R, Fu S, Zhou M, Gao Z, Fu M, Yan T, Yang Y, et al. Short-term and long-term safety and efficacy of Tenofovir alafenamide, Tenofovir disoproxil fumarate and Entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis. 2021;21(1):567.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"4289_CR27","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672\u201381.","journal-title":"J Hepatol"},{"issue":"10","key":"4289_CR28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/phar.2174","volume":"38","author":"LM Childs-Kean","year":"2018","unstructured":"Childs-Kean LM, Egelund EF, Jourjy J. Tenofovir Alafenamide for the treatment of chronic hepatitis B monoinfection. Pharmacotherapy. 2018;38(10):1051\u20137.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"4289_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"20","key":"4289_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037953","volume":"103","author":"R Liu","year":"2024","unstructured":"Liu R, Qiao J, Zhang L, Dou Z. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B. Medicine (Baltimore). 2024;103(20):e37953.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"4289_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000519440","volume":"65","author":"S Jeong","year":"2022","unstructured":"Jeong S, Shin HP, Kim HI. Real-world single-center comparison of the safety and efficacy of entecavir, Tenofovir disoproxil fumarate, and Tenofovir Alafenamide in patients with chronic hepatitis B. Intervirology. 2022;65(2):94\u2013103.","journal-title":"Intervirology"},{"issue":"4","key":"4289_CR32","first-page":"389","volume":"30","author":"FD Wang","year":"2022","unstructured":"Wang FD, Zhou J, Zhang DM, Wang ML, Tao YC, Wu DB, et al. A study of the effectiveness of nucleos(t)ide analogues in the treatment of HBeAg- positive chronic hepatitis B with normal alanine aminotransferase and high level of HBV DNA. Zhonghua Gan Zang Bing Za Zhi. 2022;30(4):389\u201394.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"3","key":"4289_CR33","first-page":"336","volume":"26","author":"D Z","year":"2023","unstructured":"Z D, X J. Early antiviral efficacy of Tenofovir Amibufenamide in treatment of Na\u00efve patients with chronic hepatitis B. J Prac Hepatol. 2023;26(3):336\u20139.","journal-title":"J Prac Hepatol"},{"issue":"08","key":"4289_CR34","first-page":"855","volume":"31","author":"C CD","year":"2023","unstructured":"CD C, GE YS. Al e: efficacy and safety of Tenofovir Alafenamide in patients with decompensated hepatitis B cirrhosis: A real-world study. Chin J Hepatol. 2023;31(08):855\u201361.","journal-title":"Chin J Hepatol"},{"issue":"07","key":"4289_CR35","first-page":"830","volume":"29","author":"T HT","year":"2024","unstructured":"HT T, JQ XW, FM Z, WH W. Clinical study of Tenofovir Alafenamide in newly treated patients with decompensated hepatitis B cirrhosis. Chin J Hepatol. 2024;29(07):830\u20133.","journal-title":"Chin J Hepatol"},{"issue":"12","key":"4289_CR36","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1016\/j.cgh.2022.12.016","volume":"21","author":"J Choi","year":"2023","unstructured":"Choi J, Lim YS, Kim JH, Byun KS, Yoo BC. Tenofovir alafenamide for multiple drug-resistant chronic hepatitis B: a 3-year clinical trial. Clin Gastroenterol Hepatol. 2023;21(12):3185-e31873182.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"4289_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","volume":"20","author":"KS Byun","year":"2022","unstructured":"Byun KS, Choi J, Kim JH, Lee YS, Lee HC, Kim YJ, et al. Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol. 2022;20(2):427-e437425.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"4289_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.14218\/JCTH.2023.00417","volume":"12","author":"J Hou","year":"2024","unstructured":"Hou J, Ning Q, Duan Z, Chen Y, Xie Q, Zhang L, Wu S, Tang H, Li J, Lin F, et al. Five-year treatment with Tenofovir Alafenamide achieves high rates of viral suppression, Alanine aminotransferase normalization, and favorable bone and renal safety in Chinese chronic hepatitis B patients. J Clin Transl Hepatol. 2024;12(5):469\u201380.","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"4289_CR39","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, et al. Long-term treatment with Tenofovir Alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2024;119(3):486\u201396.","journal-title":"Am J Gastroenterol"},{"issue":"11\u201312","key":"4289_CR40","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/apt.18278","volume":"60","author":"M Buti","year":"2024","unstructured":"Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR, et al. Eight-year efficacy and safety of Tenofovir Alafenamide for treatment of chronic hepatitis B virus infection: final results from two randomised phase 3 trials. Aliment Pharmacol Ther. 2024;60(11\u201312):1573\u201386.","journal-title":"Aliment Pharmacol Ther"},{"key":"4289_CR41","doi-asserted-by":"publisher","first-page":"S543","DOI":"10.14309\/01.ajg.0000706328.53076.1a","volume":"115","author":"M Khalili","year":"2020","unstructured":"Khalili M, Lampertico P, Bae HS, Ma X, Ramji A, Fung S, Ahn SH, Kao J-H, Tam E, Halton P, et al. S1070\u2003A phase 3 study comparing switching: Tenofovir disoproxil fumarate (TDF) to Tenofovir Alafenamide (TAF) with continued TDF treatment in virologically suppressed patients with chronic hepatitis B: final week 96 results. Official J Am Coll Gastroenterol | ACG. 2020;115:S543.","journal-title":"Official J Am Coll Gastroenterol | ACG"},{"issue":"Suppl 2","key":"4289_CR42","first-page":"A73","volume":"69","author":"SH Ahn","year":"2020","unstructured":"Ahn SH, Kao J-H, Hann H-W, Scott F, Trinh H, Nguyen TT, Paik SW, Gaggar A, Flaherty J, Yee L, et al. IDDF2020-ABS-0058\u200548-week safety and efficacy of switching to Tenofovir Alafenamide (TAF) from Tenofovir disoproxil fumarate (TDF) in chronic HBV Asian patients with TDF risk factors (RF). Gut. 2020;69(Suppl 2):A73\u20134.","journal-title":"Gut"},{"issue":"Suppl 1","key":"4289_CR43","first-page":"A142","volume":"68","author":"H Lik Yuen Chan","year":"2019","unstructured":"Lik Yuen Chan H, Lampertico P, Buti M, Fung S, Ahn SH, Chuang W-L, Tak WY, Ramji A, Chen C-Y, Tam E, et al. IDDF2019-ABS-0169\u2005A phase 3 study comparing switching from Tenofovir disoproxil fumarate (TDF) to Tenofovir Alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results. Gut. 2019;68(Suppl 1):A142\u20133.","journal-title":"Gut"},{"key":"4289_CR44","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.2147\/DDDT.S126742","volume":"11","author":"E Ogawa","year":"2017","unstructured":"Ogawa E, Furusyo N, Nguyen MH. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:3197\u2013204.","journal-title":"Drug Des Devel Ther"},{"key":"4289_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818786108","volume":"11","author":"R Byrne","year":"2018","unstructured":"Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Ther Adv Gastroenterol. 2018;11:1756284818786108.","journal-title":"Ther Adv Gastroenterol"},{"issue":"1","key":"4289_CR46","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/j.cgh.2016.09.108","volume":"15","author":"H Lik-Yuen Chan","year":"2017","unstructured":"Lik-Yuen Chan H, Fung S, Seto WK, Chuang W-L, Chen C-Y, Kim HJ, Hui AJ, Janssen H, Chowdhury A, Owen Tsang TY, et al. A phase 3 study of Tenofovir Alafenamide (TAF) compared with Tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): week 48 efficacy and safety results. Clin Gastroenterol Hepatol. 2017;15(1):e44.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"S1","key":"4289_CR47","first-page":"19","volume":"32","author":"KY Hao","year":"2024","unstructured":"Hao KY, Jiang X, Dong Y, Sun HN, Yu YC. [Evaluation of the efficacy and safety profile of Tenofovir Amibufenamide at 48 weeks during the treatment of hepatitis B virus-related cirrhosis]. Zhonghua Gan Zang Bing Za Zhi. 2024;32(S1):19\u201329.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"4289_CR48","doi-asserted-by":"publisher","first-page":"1545108","DOI":"10.3389\/fphar.2025.1545108","volume":"16","author":"X Qiu","year":"2025","unstructured":"Qiu X, Yin Y, Zhang S, Liu W. Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study. Front Pharmacol. 2025;16:1545108.","journal-title":"Front Pharmacol"},{"issue":"11","key":"4289_CR49","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jgh.14686","volume":"34","author":"S Kaneko","year":"2019","unstructured":"Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, et al. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. J Gastroenterol Hepatol. 2019;34(11):2004\u201310.","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"4289_CR50","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00535-020-01698-4","volume":"55","author":"MR Charlton","year":"2020","unstructured":"Charlton MR, Alam A, Shukla A, Dashtseren B, Lesmana CRA, Duger D, Payawal DA, Duy Cuong D, Jargalsaikhan G, Cua IHY, et al. An expert review on the use of Tenofovir Alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020;55(9):811\u201323.","journal-title":"J Gastroenterol"},{"key":"4289_CR51","doi-asserted-by":"crossref","unstructured":"Cathcart AL, Chan HL-Y, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, Shalimar, Buti M, Cox S, Parhy B et al: No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrobial Agents and Chemotherapy 2018, 62(10):10.1128\/aac.01064-01018.","DOI":"10.1128\/AAC.01064-18"},{"issue":"11","key":"4289_CR52","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/jvh.13603","volume":"28","author":"HJ Tsai","year":"2021","unstructured":"Tsai HJ, Chuang YW, Yang SS, Chang YZ, Chang HR, Lee TY. Evaluating the renal safety of Tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease. J Viral Hepat. 2021;28(11):1579\u201386.","journal-title":"J Viral Hepat"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04289-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04289-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04289-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:02:33Z","timestamp":1761318153000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04289-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4289"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04289-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review and network meta-analysis based solely on published aggregate data; no new data from individual patients were collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"760"}}